Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$55,777,839
+$13,548,436 QoQ
Shares Held
533,147
+44.1% QoQ
Ownership
1.09%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#23
of 274 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Holocene Advisors, LP holds $1,266,200,483 across 29 Biotechnology names. CELC ranks #11 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
1,359,269 | $254,563,898 | |
| 2 | DNLI |
Denali Therapeutics Inc.
|
3,905,225 | $100,442,387 | |
| 3 | CYTK |
Cytokinetics Inc
|
1,144,579 | $97,506,685 | |
| 4 | SRRK |
Scholar Rock Holding Corp
|
1,755,978 | $96,578,790 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
1,106,177 | $90,164,487 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,015,170 | $90,126,792 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
152,924 | $82,112,541 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
|
2,410,939 | $75,365,953 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $55,777,839 | 533,147 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $42,229,403 | 369,979 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $69,353,211 | 695,340 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||